Aytu BioPharma, Inc.

NasdaqCM:AYTU Stock Report

Market Cap: US$10.3m

Aytu BioPharma Management

Management criteria checks 2/4

Aytu BioPharma's CEO is Josh Disbrow, appointed in Apr 2015, has a tenure of 9.75 years. total yearly compensation is $928.22K, comprised of 63.6% salary and 36.4% bonuses, including company stock and options. directly owns 1.17% of the company’s shares, worth $120.47K. The average tenure of the management team and the board of directors is 2.6 years and 8.5 years respectively.

Key information

Josh Disbrow

Chief executive officer

US$928.2k

Total compensation

CEO salary percentage63.6%
CEO tenure9.8yrs
CEO ownership1.2%
Management average tenure2.6yrs
Board average tenure8.5yrs

Recent management updates

It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Jun 20
It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Recent updates

Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For Growth

Jan 18
Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For Growth

Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32%

Nov 15
Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32%

Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?

Nov 01
Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?

It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Jun 20
It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

Jun 14
Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Feb 17
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Feb 16
Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Jan 23
Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Sep 29
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Aytu stock falls amid suspending clinical programs to save costs

Oct 13

Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M

Sep 27

Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder

Sep 14

Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders

Aug 16

Aytu BioPharma plunges on pricing $10M stock and warrants offering

Aug 09

Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

May 19
Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Sep 11
Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Aytu BioPharma up 21% in afternoon trading

Jun 21

CEO Compensation Analysis

How has Josh Disbrow's remuneration changed compared to Aytu BioPharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$7m

Jun 30 2024US$928kUS$590k

-US$16m

Mar 31 2024n/an/a

-US$13m

Dec 31 2023n/an/a

-US$17m

Sep 30 2023n/an/a

-US$24m

Jun 30 2023US$708kUS$590k

-US$17m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022n/an/a

-US$77m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022US$590kUS$590k

-US$109m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021n/an/a

-US$84m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021US$6mUS$545k

-US$58m

Mar 31 2021n/an/a

-US$42m

Dec 31 2020n/an/a

-US$22m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020US$2mUS$608k

-US$14m

Mar 31 2020n/an/a

-US$25m

Dec 31 2019n/an/a

-US$24m

Sep 30 2019n/an/a

-US$29m

Jun 30 2019US$1mUS$330k

-US$27m

Mar 31 2019n/an/a

-US$12m

Dec 31 2018n/an/a

-US$10m

Sep 30 2018n/an/a

-US$9m

Jun 30 2018US$606kUS$303k

-US$10m

Compensation vs Market: Josh's total compensation ($USD928.22K) is above average for companies of similar size in the US market ($USD645.26K).

Compensation vs Earnings: Josh's compensation has increased whilst the company is unprofitable.

CEO

Josh Disbrow (49 yo)

9.8yrs

Tenure

US$928,217

Compensation

Mr. Joshua R. Disbrow, also known as Josh, serves as Chief Executive Officer at Aytu Biopharma, Inc. since April 16, 2015 and served as its Chairman until 2024. He served as President at Aytu Biopharma, In...

Leadership Team

NamePositionTenureCompensationOwnership
Joshua Disbrow
CEO & Director9.8yrsUS$928.22k1.17%
$ 120.5k
Jarrett Disbrow
Chief Business Officer2.2yrsUS$542.10k0.21%
$ 21.5k
Greg Pyszczymuka
Chief Commercial Officer3yrsUS$516.30k0.38%
$ 39.3k
Ryan Selhorn
CFO, Corporate Secretary & Treasurerless than a yearno data0.26%
$ 26.7k
Margaret Cabano
Vice President of Operationsno datano datano data

2.6yrs

Average Tenure

46.5yo

Average Age

Experienced Management: AYTU's management team is considered experienced (2.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Joshua Disbrow
CEO & Director9yrsUS$928.22k1.17%
$ 120.5k
Vivian Liu
Independent Director2.5yrsUS$77.60k0.16%
$ 16.5k
John Donofrio
Independent Chairman8.5yrsUS$107.60k0.061%
$ 6.3k
Carl Dockery
Independent Director8.8yrsUS$72.60k0.17%
$ 17.5k
Abhinav Jain
Independent Director1.6yrsUS$79.30k0.15%
$ 16.0k

8.5yrs

Average Tenure

57yo

Average Age

Experienced Board: AYTU's board of directors are considered experienced (8.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/22 23:30
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aytu BioPharma, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jennifer KimCantor Fitzgerald & Co.
Jeffrey CohenLadenburg Thalmann & Company
Nazibur RahmanMaxim Group